Last reviewed · How we verify
Atenolol Succinate Oral Tablet
Atenolol succinate is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of catecholamines on the heart.
Atenolol succinate is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of catecholamines on the heart. Used for Hypertension, Angina pectoris, Acute myocardial infarction.
At a glance
| Generic name | Atenolol Succinate Oral Tablet |
|---|---|
| Also known as | Tenormin tablets |
| Sponsor | Damanhour Teaching Hospital |
| Drug class | Beta-1 selective adrenergic antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atenolol selectively blocks beta-1 adrenergic receptors on cardiac tissue, decreasing heart rate, contractility, and cardiac output. This leads to reduced blood pressure and myocardial oxygen demand. The succinate salt formulation is an extended-release variant designed to provide sustained therapeutic levels.
Approved indications
- Hypertension
- Angina pectoris
- Acute myocardial infarction
- Atrial fibrillation for rate control
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Cold extremities
- Dyspnea
- Insomnia
Key clinical trials
- Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries (PHASE4)
- Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atenolol Succinate Oral Tablet CI brief — competitive landscape report
- Atenolol Succinate Oral Tablet updates RSS · CI watch RSS
- Damanhour Teaching Hospital portfolio CI